This adverse event occurred in the absence of a major cardiovascular risk factor, hemodynamic instability, or hypercoagulability state, thus excluding major conditions predisposing the onset of this acute event
This rash may appear as redness, bumps, or hives and is typically a localized reaction to the medication or the injection process
The FDA added it to injectable semaglutide in January 2025, and it climbs the dose axis like everything else. Burning or tingling skin tracks the dose, not the weight lost, and an active-comparator study put the risk about twice that of another weight-loss drug. The mechanism is unsettled: the tempting "it is the drugs signaling arm" story is ruled out, because the strongest GLP-1 signaler in the class carries no such signal
Obinwanne, K
Clinical Studies 14.1 Glycemic Control Trials in Adults with Type 2 Diabetes Mellitus OZEMPIC has been studied as monotherapy and in combination with metformin, metformin and sulfonylureas, metformin and/or thiazolidinedione, and basal insulin in patients with type 2 diabetes mellitus
Product Overview AOD-9604 5mg vial *Needs mixing - add BAC water to your cart